Quick Answer
Acumen Pharmaceuticals, Inc. reported Long-Term Debt of $22.40 million for fiscal year 2025.
Acumen Pharmaceuticals, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $22.40M | -23.9% |
| 2024 | $29.42M | -1.6% |
| 2023 | $29.90M | — |
| 2022 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $27.05M | -8.8% | -9.5% |
| June 30, 2025 | $29.88M | +1.7% | +1.2% |
| March 31, 2025 | $29.53M | -2.3% | +0.4% |
| December 31, 2024 | $29.42M | -1.6% | -0.9% |
| September 30, 2024 | $29.67M | — | +1.0% |
| June 30, 2024 | $29.38M | — | -2.7% |
| March 31, 2024 | $30.21M | — | +1.0% |
| December 31, 2023 | $29.90M | — | — |
- Acumen Pharmaceuticals, Inc. showed a decrease of -23.9% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from Acumen Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: